Vyleesi and Exercise: What to Know About Using Bremelanotide During Your Active Life

What Vyleesi Actually Does in Your Body

Bremelanotide works by activating melanocortin receptors, specifically MC1R and MC4R, in the central nervous system. Hypoactive sexual desire disorder (HSDD) is characterized by persistently low sexual desire that causes marked distress, and bremelanotide is the only on-demand, non-hormonal option approved for it in premenopausal women.

Unlike flibanserin (Addyi), which you take daily, Vyleesi is a subcutaneous auto-injector used only when you anticipate sexual activity. That on-demand structure is clinically meaningful: your exposure is episodic, not continuous, which changes how you think about daily-life planning, including exercise.

The Pharmacokinetics That Matter for Active Women

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration in roughly 1 hour. The elimination half-life is approximately 2.7 hours, meaning the drug is largely cleared within 12 hours. For a woman who jogs at 6 a.m. And uses Vyleesi the evening before, pharmacokinetic overlap is minimal. For a woman who uses it mid-afternoon before a 5 p.m. Spin class, timing becomes something to think through deliberately.

Melanocortin Receptors and Cardiovascular Response

The same MC1R/MC4R activity that influences sexual desire also acts on vascular smooth muscle. This produces the drug's most clinically relevant cardiovascular effect: a transient increase in blood pressure paired with a decrease in heart rate. In pooled phase 3 data, mean maximum systolic BP rose approximately 6 mmHg and diastolic BP rose approximately 4 mmHg, peaking around 12 minutes post-injection and returning to baseline within 12 hours in most women.

Vigorous aerobic exercise independently raises systolic BP by 30 to 50 mmHg. Stacking a drug-induced BP rise on top of exercise-induced elevation is the core reason clinicians advise against hard training sessions in the hours immediately following a dose.

Nausea: The Side Effect That Most Disrupts Daily Life

Nausea is the most frequently reported side effect of bremelanotide, and it is the reason many women adjust their schedules far more than the cardiovascular effect requires. In the RECONNECT phase 3 trials, approximately 40% of women who received bremelanotide reported nausea, compared with roughly 1% in the placebo arm. About 13% of participants discontinued the drug because of nausea.

That is a real number. Nearly 1 in 8 women stops using Vyleesi because the nausea is intolerable, so if you are experiencing it, you are not alone, and the decision to stop is clinically supported.

Why Nausea Matters Specifically for Exercise

Running, cycling, high-intensity interval training, and even hot yoga all independently worsen nausea. Dehydration, which exercise accelerates, compounds it further. If your dose produces even moderate nausea and you attempt a vigorous workout 30 to 90 minutes later, you are likely to feel significantly worse than either cause alone would produce.

Practical Nausea Management

The FDA label notes that a prescribed antiemetic can be taken before bremelanotide to reduce nausea severity. In the RECONNECT trials, pre-treatment with ondansetron 4 mg oral reduced the incidence and severity of nausea without appearing to affect the drug's efficacy signal. Your prescriber may offer this prophylactically or as a rescue option.

Practical steps women report finding helpful in observational surveys include:

• Injecting at least 90 minutes before any planned physical activity, not the minimum 45 minutes.
• Staying well hydrated before and after the dose.
• Avoiding heavy meals immediately before the injection, since a full stomach seems to worsen nausea for many users.
• Starting with light activity (a slow walk, gentle stretching) to gauge individual response before returning to high-intensity training.

No randomized trial has tested these strategies specifically, so the evidence here is observational and extrapolated from general antiemetic management principles.

Exercise, Blood Pressure, and Cardiovascular Safety

The transient blood pressure increase from bremelanotide is small in absolute terms for most healthy premenopausal women. The FDA prescribing information contraindicates bremelanotide in women with known cardiovascular disease, and it states that blood pressure should return to pre-dose levels within 12 hours. Women with pre-existing hypertension were excluded from the RECONNECT trials, so there is essentially no safety data in that group.

Who Should Be More Cautious About Exercise Timing

If any of the following apply to you, discuss the exercise question explicitly with your prescriber before your first dose:

• Resting systolic BP consistently above 130 mmHg
• A history of orthostatic hypotension (the drug may cause flushing and a transient drop in some women)
• Use of antihypertensive medications
• Migraine with aura (the drug also causes transient facial flushing and headache in some women, which can overlap symptomatically with migraine prodrome)

Women With PCOS and Metabolic Considerations

Women with PCOS often have a higher baseline prevalence of hypertension and insulin resistance than age-matched peers. A 2022 analysis in Fertility & Sterility noted that cardiovascular risk factors are significantly more common in women with PCOS than in the general population. If you have PCOS and are using Vyleesi, the blood pressure conversation with your provider is not optional, it is a necessary part of the treatment plan.

Timing Your Dose Around Your Schedule: A Practical Framework

There is no published clinical algorithm for coordinating bremelanotide use with exercise schedules. The following framework is based on the drug's pharmacokinetic profile, the known peak and duration of blood pressure effects, and the clinical reasoning applied at WomanRx. It is meant to structure a conversation with your provider, not to replace one.

Window 1: Injection to 2 hours post-dose Blood pressure is at or near peak elevation during this window. Nausea, if it occurs, is also most prominent here. Avoid vigorous aerobic exercise, resistance training at maximal loads, and hot environments (saunas, hot yoga). Light walking is generally fine if you feel well.

Window 2: 2 to 6 hours post-dose For most women, BP is trending back toward baseline. Nausea is usually resolving. Moderate-intensity activity (a brisk walk, light cycling, low-load strength work) is reasonable if you feel symptom-free.

Window 3: 6 to 12 hours post-dose The drug is in late elimination. BP is expected to be at or near baseline. Return to normal training intensity is appropriate for most women with no cardiovascular risk factors.

Window 4: Greater than 12 hours post-dose Full return to any exercise intensity is appropriate. If you train in the morning and use Vyleesi the previous evening, you are in this window.

Life-Stage Considerations Across the Reproductive Years

Women in Their 20s and 30s (Reproductive Years)

HSDD in younger premenopausal women is more commonly associated with hormonal contraception, relationship factors, trauma history, and mood disorders than with the hormonal shifts of aging. A 2016 study in JAMA Internal Medicine found that women using combined oral contraceptives were nearly twice as likely to report HSDD symptoms as non-users. If you are in this group and using Vyleesi, the active lifestyle piece of the conversation should also include your contraceptive method, since hormonal contraception can suppress free testosterone, which compounds HSDD.

Exercise itself is a co-intervention worth mentioning. Regular moderate aerobic exercise has been associated with improved sexual function and reduced HSDD symptom severity in observational studies, though it does not replace pharmacotherapy when the disorder is clinically significant.

Perimenopause

Bremelanotide is approved for premenopausal women only. The trials did not enroll perimenopausal women as a defined subgroup, and the FDA label does not address this population specifically. The Menopause Society (formerly NAMS) 2022 position statement on sexual function notes that low desire in the menopausal transition is common and often has mixed hormonal and psychosocial contributors. Off-label use in perimenopause occurs clinically, but evidence is essentially absent. If your clinician is considering bremelanotide during perimenopause, that conversation should include what the evidence gap means for you.

Exercise during perimenopause carries its own considerations: vasomotor symptoms can mimic some Vyleesi side effects (flushing, warmth, elevated heart rate), potentially making it harder to distinguish a drug effect from a hot flash. Keeping a symptom log the first few times you use the drug helps establish your individual baseline.

Postmenopause

Vyleesi is not approved for postmenopausal women. The phase 3 trials specifically enrolled premenopausal women experiencing HSDD unrelated to a co-existing medical or psychiatric condition. Postmenopausal women with low desire have other evidence-based options, including topical estrogen for genitourinary syndrome of menopause (GSM) and, in select cases, low-dose testosterone (off-label in the US, approved in Australia and the UK).

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory information, not fine print.

Pregnancy

Bremelanotide is contraindicated in pregnancy. The FDA prescribing information states that animal studies showed fetal harm at doses relevant to human exposure, including reduced fetal survival and growth. Human data are absent because pregnant women were excluded from all trials. The drug is classified as a pregnancy category with known fetal risk signals in animal data. If you discover you are pregnant, stop the drug immediately and contact your obstetric provider.

Because HSDD for which Vyleesi is prescribed may coexist with active attempts to conceive (particularly in women with relationship-based desire discrepancy who are not using contraception), this creates a practical dilemma. The drug should not be used by women who are actively trying to conceive.

Lactation

There are no human data on bremelanotide transfer into breast milk. The FDA label recommends against use during breastfeeding based on the potential for adverse effects in the nursing infant and the absence of any safety data. If you are postpartum and breastfeeding and experiencing low desire (an extremely common postpartum experience driven by prolactin elevation and sleep deprivation), bremelanotide is not currently an appropriate option. Discuss timing and alternative approaches with your provider.

Contraception

Women using bremelanotide who do not want to become pregnant should use reliable contraception. The drug does not function as a contraceptive. If you are using a copper IUD, progestin-only implant, or other highly effective method, no additional steps are needed. If you rely on oral contraceptives, be aware that OCP use is itself associated with HSDD, a circularity worth discussing with your prescriber.

Flushing, Headache, and Other Side Effects That Touch Daily Activity

Beyond nausea and blood pressure, two additional side effects appear frequently enough to affect daily life planning.

Facial and body flushing occurs in roughly 20% of women in trials. It can last 1 to 2 hours and may be visible or uncomfortable enough to interfere with work, social plans, or the gym. For some women, flushing is mild and cosmetically acceptable. For others, it is the primary reason they restrict their use to evenings or weekends.

Headache occurs in roughly 11% of women. Per the FDA label, it is usually mild to moderate and self-limiting. Exercise-induced headache on its own is a recognized phenomenon; if you are prone to it, combining a dose with a hard training session may increase headache risk, though this specific interaction has not been studied.

Injection site reactions (bruising, pain, localized erythema) are reported by approximately 18% of women. For women who use the thigh as the injection site and perform lower-body strength training, timing the injection on the non-dominant or less-loaded side may reduce discomfort.

What Women Are Actually Reporting: Real-World Experience

Randomized trial data on bremelanotide covers efficacy and primary safety endpoints. It does not cover questions like "Can I go to the gym after I use this?" because those outcomes were not measured. What exists is a growing body of patient-reported experience from observational contexts.

A 2021 survey-based analysis published in Sexual Medicine found that women who continued using bremelanotide beyond the initial trial period did so selectively, most commonly on weekends or evenings when scheduling flexibility reduced the conflict between side effects and daily obligations. Women who discontinued most often cited nausea as the reason, with the second most common reason being that the 45-minute anticipation window felt too new to spontaneity.

The women who reported the best experience shared a common strategy: they treated the drug as a planned event rather than a spontaneous one, and they structured the evening (or morning, or afternoon) to allow for the nausea and flushing window to pass before committing to any strenuous activity.

This is not a failure of the drug. It is a realistic description of what on-demand pharmacotherapy for a complex condition looks like in practice.

Living With Vyleesi: The Broader Daily-Life Picture

Sleep

The drug's half-life of approximately 2.7 hours means a dose taken at 9 p.m. Has meaningful plasma levels through midnight and diminishing levels into the early morning. For most women, this does not disrupt sleep architecture, but if you are sensitive to the flushing or mild elevation in heart rate, you may notice it in the first 1 to 2 hours of trying to sleep.

Alcohol

No formal alcohol interaction study has been published. Given that alcohol also causes vasodilation and can lower BP after an initial elevation, the combination theoretically affects blood pressure in unpredictable directions. The FDA label does not specify a restriction, but moderate use (one drink) appears to be the practical ceiling that most clinical settings suggest.

Mood and Appetite

Melanocortin receptors (MC4R in particular) are involved in both appetite regulation and mood signaling. A 2019 review in Endocrinology described the MC4R pathway as integral to energy homeostasis, with downstream effects on feeding behavior. In the RECONNECT trials, no significant changes in weight or appetite were reported at the dose and frequency studied (up to once per 24 hours, episodic use). However, women who use the drug more frequently than intended or who are sensitive to melanocortin signaling may notice mild appetite suppression, which could affect fueling around workouts.

Skin and Hair (Hyperpigmentation)

Bremelanotide activates MC1R, which drives melanin synthesis. The FDA label notes that focal hyperpigmentation of the face, breast, gums, and other areas can develop with repeated use. This effect is more pronounced in women with darker skin tones. If you spend significant time in the sun (including outdoor exercise), UV exposure may compound the hyperpigmentation risk. Sun protection on exposed areas is a reasonable precaution during active treatment.

Who This Is Right for, and Who Should Reconsider

Women Who Are Likely Good Candidates

• Premenopausal women with a confirmed HSDD diagnosis (not desire discrepancy alone)
• Women who prefer on-demand dosing over a daily medication
• Women whose schedules allow a 2 to 3-hour buffer after a dose before demanding physical activity
• Women without significant cardiovascular risk factors, hypertension, or cardiovascular disease

Women Who Should Have a Careful Conversation First

• Women with resting hypertension or on antihypertensive therapy (excluded from trials; no safety data)
• Women with a history of migraines with aura (flushing and headache overlap symptomatically)
• Women with PCOS and cardiovascular risk factors (see above)
• Women who are pregnant, trying to conceive, or breastfeeding (contraindicated or unsupported by data)
• Women whose exercise schedule is daily and high-intensity and who cannot readily adjust timing

The Evidence Gap Worth Naming Plainly

The RECONNECT trials enrolled premenopausal women in a narrow clinical definition of HSDD. Per the trial design described in the NEJM evidence review, women with significant medical comorbidities, hormonal disorders, and relationship distress as the primary contributor to low desire were excluded. Real-world users are a broader, messier population. Exercise interaction data does not exist in any published trial. The blood pressure and nausea data are the best proxies we have, and the clinical reasoning in this article is built from those proxies, not from direct exercise-drug interaction studies. That gap should be part of your informed consent conversation.